Can doctors and patients suss out misleading information in drug ads? That’s what the FDA wants to find out. In a proposed pair of studies, the agency will look at healthcare providers’ and patients’ responses to determine their ability to detect different levels and types of deception.
The proposal was posted in the Federal Register on Jan. 4 and is open for public comment until March 6, an FDA spokeswoman told FiercePharma via email.
